A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components



Status:Enrolling by invitation
Conditions:Hospital
Therapuetic Areas:Other
Healthy:No
Age Range:Any
Updated:2/13/2019
Start Date:December 2015
End Date:December 2020

Use our guide to learn which trials are right for you!

A Prospective, Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components

This study is a prospective, non-randomized sequential cohort, open label, multi-center,
non-inferiority, Phase IV surveillance study following transfusion of INTERCEPT PCs. The
patient population will be hematology-oncology patients, including those undergoing
hematopoietic stem cell transplant (HSCT), expected to require one or more PC transfusions.

For each participating center, the study will start with a brief pilot run-in period with a
group of at least 5 patients exposed only to conventional PCs. The purpose of this pilot
run-in is to evaluate study logistics and data collection methods within each study center.
Data from the pilot phase will be included in the data listings but not included for the
treatment comparison.

After the pilot run-in period, the study will be conducted in two sequential patient cohorts:
1) the Control cohort during which study patients will receive only conventional PCs, and 2)
the INTERCEPT cohort during which patients will receive only INTERCEPT PCs. Patient
enrollment at each Center will be monitored to target similar numbers of patients into the
Control and Test Cohorts within each center. Within each Center, patient enrollment will be
stratified in four categories: (1) chemotherapy only; and by use of conditioning regimens for
hematopoietic stem cell transplantation (HSCT) in (2) myeloablative conditioning, (3)
non-myeloablative conditioning, and (4) reduced intensity using the Center for International
Blood and Marrow Transplant Research (CIBMTR) criteria. To ensure both Test and Control
cohorts have a similar allocation ratio (±10% per category) among the conditioning regimen
strata, enrollment caps will be set for the Test cohorts, hence no Test patients will be
enrolled to a stratum once the cap for the given stratum is met.

The study will have a pilot run-in period and two sequential cohort groups for each center.

Pilot Run-in Period The pilot run-in period will be conducted in each center with a group of
at least 5 patients exposed only to conventional PCs, who provide informed consent for data
collection. The purpose of this pilot run-in is to evaluate study logistics and data
collection methods within each study center. Data collection will not differ from that
required in the two sequential patient cohorts. The data from the pilot phase will be
included in the data listings but not included for the treatment comparisons.

Control and INTERCEPT Cohorts Following the run-in period, the study will be conducted in two
sequential cohort periods. Informed consent for data collection without study specific
treatment intervention, and under patient confidentiality, will be required for both cohorts
prior to any study procedure.

During the Control cohort period, patients will have study data collected following
transfusion with only conventional PCs for up to 21 days of transfusion support, as
clinically indicated in a manner that is consistent with the local standard of care. During
the INTERCEPT phase, patients will receive only INTERCEPT PCs under the same clinical
treatment guideline. Patients will be transfused with only study PCs of the assigned
treatment type (Conventional or INTERCEPT) in each cohort. Enrollment will be stratified by
study center and type of primary disease therapy (autologous HSCT, allogeneic HSCT, cord
blood HSCT, and chemotherapy).

For both cohorts, patients will be supported with study PC transfusions for a maximum of 21
days or until platelet transfusion independence. Patients are considered to have achieved
platelet transfusion independence if more than 5 days elapse after exposure to a study PC
transfusion. When a patient achieves platelet independence, the patient will have completed
the study PC transfusion period (even if they subsequently resume another cycle of platelet
support).

Data collection for all participants will comprise: patient baseline disease characteristics,
including primary disease, type of HSCT (auto, allo, cord blood, matched related or matched
unrelated) or type of chemotherapy, and medications at study entry and during the study
observation period. Patient clinical respiratory status, including a chest imaging study at
baseline prior to the first study transfusion in each cohort period, will be also be
recorded.

Within each study cohort, patients will be assessed for the primary outcome measure of
assisted ventilation for a maximum of 28 days (7 days surveillance following up to of 21 days
of study PC transfusion support). Furthermore, AEs (including TRs) will be collected from the
primary medical record for 24 hours following the initiation of each study PC transfusion.;
SAEs (including ARDS), Grade 2 or higher AEs affecting the Respiratory System, and mortality
will be collected for 7 days post each study transfusion (or until hospital
discharge/discontinuation of outpatient platelet transfusion support, whichever is sooner).
Investigators will assess the intensity of each AE and SAE and provide their assessment of
the relationship of each AE and SAE to the study transfusion. Patients who experience the
outcome of assisted ventilation, ARDS, or Grade 2 or higher AEs affecting the Respiratory
System will be assessed as detailed in Assessment of Pulmonary Adverse Events in the synopsis
and in Protocol Section 8.1.

For patients who achieve platelet independence before Study Day 21, AEs will be collected for
24 hours after initiating the last study platelet transfusion prior to platelet independence;
the outcome of assisted ventilation, SAEs, ARDS, Grade 2 or higher AEs affecting the
Respiratory System, and mortality will be collected for 7 days after the last study PC
transfusion prior to platelet independence (or until hospital discharge/discontinuation of
outpatient platelet transfusion support, whichever is sooner).

For patients who require more than 21 days of PC transfusion support, AEs will be recorded
for up to 24 hours after the initiation of the last platelet transfusion up to and including
Day 21; the outcome of assisted ventilation, SAEs, ARDS, Grade 2 or higher AEs affecting the
Respiratory System, and mortality will be collected for up to a maximum of 28 days (7 days
after up to 21 days of platelet transfusion support),7 days after initiating the last study
transfusion within the 21-day study transfusion period (or until hospital
discharge/discontinuation of outpatient platelet transfusion support, whichever is sooner).

Study-specific research personnel will review the patient medical record and record study
outcomes on electronic Case Report Forms (eCRF). The intensity of AEs and SAEs will be graded
according to the most recent version of the Common Terminology Criteria for Adverse Events
(CTCAE) classification system. The AEs and SAEs will be coded using MedDRA (Version 18.0 or
higher). TRs will also be assessed following the CDC National Healthcare Safety Network
(NHSN) Biovigilance Component Hemovigilance Module Surveillance Protocol (NHSN Protocol).

Inclusion Criteria:

- Patients with a hematology-oncology disorder expected to require or requiring a
transfusion of one or more PCs.

- Written signed informed consent (unless exemption of individual consent is granted by
the center's IRB).

Exclusion Criteria:

- Assisted ventilation (administered by intubation or tight fitting mask with PEEP or
CPAP ≥ 5 cm H2O) prior to the first study PC transfusion of a cohort period.

- Documented allergy to psoralens
We found this trial at
13
sites
1851 Macgregor Downs Road
Greenville, North Carolina 27834
?
mi
from
Greenville, NC
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
(612) 625-5000
Univ of Minnesota With a flagship campus in the heart of the Twin Cities, and...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
1211 Medical Center Dr
Nashville, Tennessee 37232
(615) 322-5000
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Baltimore, Maryland 20742
(301) 405-1000
University of Maryland As a globally-connected university offering a world-class education, the University of Maryland...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Boston, Massachusetts
?
mi
from
Boston, MA
Click here to add this to my saved trials
7777 Beechmont Avenue
Cincinnati, Ohio 45220
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
20 York St, N20 York St,
New Haven, Connecticut 06520
(203) 688-4242
Yale-New Haven Hospital Relying on the skill and expertise of more than 4,500 university and...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
New York, New York 10065
?
mi
from
New York, NY
Click here to add this to my saved trials
Palo Alto, California 94304
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Rochester, New York 14642
?
mi
from
Rochester, NY
Click here to add this to my saved trials
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials